Avalyn Q2 2026: $413.5M Cash, MIST Over-Enrolled, Topline Data in H2 2027
AVLN sits 45% above its 52-week low of $24.15.
Summary
Avalyn Pharma reported Q2 2026 financials with $413.5M in cash, funding operations into 2029. The MIST Phase 2b trial over-enrolled to 398 patients, with topline data expected in H2 2027.
Key Events · Earnings and Guidance · AVLN
-
Q2 2026 Financial Results
Net loss of $28.9M on R&D spend of $24.7M and G&A of $6.6M. Cash, equivalents, and marketable securities totaled $413.5M as of June 30, 2026, with runway projected into 2029.
-
MIST Phase 2b Trial Over-Enrolled
Enrollment completed with 398 patients, exceeding the 375-patient target. Topline data from the 52-week study in progressive pulmonary fibrosis expected in H2 2027.
-
Pipeline Progress Across Programs
AURA Phase 2 trial of AP02 in IPF on track for topline data in late 2027. AP03 Phase 1 trial on track to initiate by end of 2026. Two abstracts accepted for ERS Congress in September 2026.
-
Strong Cash Runway Removes Financing Overhang
The $413.5M cash position, bolstered by $316.6M in net IPO proceeds, funds operations into 2029, eliminating near-term dilution risk.
Analysis · AVLN · Life Sciences
Avalyn Pharma delivered a clean Q2 2026 update with no surprises. The $413.5 million cash position extends runway into 2029, removing near-term financing risk. The MIST Phase 2b trial over-enrolled to 398 patients, signaling strong investigator and patient interest in AP01 for progressive pulmonary fibrosis. Topline data is still 12–18 months away, so this is a steady-state execution update rather than a catalyst. The stock is trading near its 52-week high, reflecting market confidence in the pipeline.
At the time of this filing, AVLN was trading at $35.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $24.15 to $35.84. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.